Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07648420 · ClinicalTrials.gov registry record · NA
Using Apollo Neuro in Autistic Children With Self-Injurious Behavior
A NA study, sponsored by Virginia Commonwealth University.
- Not yet
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT07648420: Clinical Trial NA study, sponsored by Virginia Commonwealth University.
NCT07648420 is a NA study that has not yet begun recruiting, run by Virginia Commonwealth University. The registered enrollment target is 18 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07648420, a NA study, has not yet begun recruiting, sponsored by Virginia Commonwealth University.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study will evaluate the feasibility and acceptability of the Apollo Neuro, a wearable vibrotactile sensory device, in autistic children who engage in self-injurious behavior (SIB). Participants will wear the device for at least 3 hours per day over a 30-35 day period with caregiver support. Outcomes will include adherence to device use, caregiver-reported feasibility and acceptability, and descriptive characterization of caregiver-reported self- injurious and repetitive behaviors during the study period. This preliminary, single-group study is not designed to evaluate efficacy and will inform the design of future controlled trials.
Primary Outcome
Caregiver-reported acceptability of the intervention, as measured by the Acceptability of Intervention Measure (AIM), a validated 4-item instrument assessing the perceived agreeableness, satisfaction, and usability of the intervention. Each item is rated on a 5-point Likert scale ranging from 1 (Completely disagree) to 5 (Completely agree). Responses will be summarized descriptively using mean scores and response distributions.
Interventions
- DEVICE Apollo Neuro device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-07 |
| Est. Completion | 2026-11 |
| Phase | NA |
What is known before NCT07648420 opens enrollment
NCT07648420 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Apollo Neuro device is the first listed.
NCT07648420 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07648420 about?
NCT07648420 is a clinical study titled "Using Apollo Neuro in Autistic Children With Self-Injurious Behavior". This study will evaluate the feasibility and acceptability of the Apollo Neuro, a wearable vibrotactile sensory device, in autistic children who engage in self-injurious behavior (SIB). Participants will wear the device for at least 3 hours per day over a 30-35 day period with caregiver support. Ou...
What is the current status of trial NCT07648420?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 18 participants. The study started on 2026-07. Estimated completion is 2026-11.
What interventions are being tested in trial NCT07648420?
The interventions under investigation include: Apollo Neuro device (DEVICE).
Who is sponsoring clinical trial NCT07648420?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07648420's enrollment target sits among peer trials
18 1863rd of 2000 higher than 130 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia